Obicetrapib hemicalcium
Based on 1 publication(s) in Google Scholar
Obicetrapib hemicalcium (TA-8995; DEZ-001) is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib hemicalcium potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib hemicalcium can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD).
For research use only. We do not sell to patients.
- CAS No.: 866399-89-5
- Formula: C32H31F9N4O5·1/2Ca
- Molecular Weight:742.65
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
|
apoB |
CETP |
In Vitro
Chemical Information
-
CAS No. 866399-89-5
-
Molecular Weight 742.65
-
Formula C32H31F9N4O5·1/2Ca
-
SMILES
FC(F)(F)C1=CC(C(F)(F)F)=CC(CN(C2=NC=C(OCCCC(O)=O)C=N2)[C@@H]3C4=CC(C(F)(F)F)=CC=C4N([C@@H](C3)CC)C(OCC)=O)=C1.[Ca].[1/2]
-
Synonyms
TA-8995 hemicalcium; DEZ-001 hemicalcium; AMG-899 hemicalcium
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Obicetrapib hemicalcium
- 866399-89-5
- TA-8995 hemicalcium
- DEZ-001 hemicalcium
- AMG-899 hemicalcium
- CETP
- Apolipoprotein
- LPL Receptor
- LDLR
- Cholesteryl ester transfer protein
- Lysophospholipid Receptor
- Low-density lipoprotein receptor
- very low-density lipoprotein
- high-density lipoprotein
- dyslipidemia
- low-density lipoprotein
- apolipoprotein B
- cholesteryl esters
- cholesteryl ester transfer protein
- atherosclerotic cardiovascular disease
- triglycerides
- Inhibitor
- inhibitor
- inhibit